Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

IDH1 Mutant AML Is Susceptible to Targeting De Novo Lipid Synthesis Independent of 2-Hydroxyglutarate and Has a Distinct Metabolic Profile from IDH2 Mutant AML

Daniel Thomas, MD PhD, Yusuke Nakauchi, MD PhD, Manhong Wu, PhD, Ming Zheng, PhD, Subarna Sinha, PhD, David Dill, PhD, Gary Peltz, MD PhD, Ravindra Majeti, MD PhD

Blood (2018) 132 (Supplement 1): 440.

https://doi.org/10.1182/blood-2018-99-115040

Published: 2018

Journal Articles

Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial.

Giuseppe Saglio, MD, PhD, Richard A. Larson, MD, Timothy P. Hughes, MD, MBBS, Surapol Issaragrisil, MD, Anna G. Turkina, MD, PhD, David Marin, MD, FRCP, Maria Zanichelli, MD, Hirohiko Shibayama, MD, PhD, Matt E. Kalaycio, MD, Francoise Rigal-Huguet, MD, Neil J. Gallagher, MD, PhD, Marcia Kayath, MD, Ming Zheng, PhD, Hagop Kantarjian, MD, Andreas Hochhaus, MD

Blood (2010) 116 (21): 3430.

https://doi.org/10.1182/blood.V116.21.3430.3430

Published: 2010

Journal Articles

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

Blood (2008) 111 (4): 1834–1839.

https://doi.org/10.1182/blood-2007-04-083196

Published: 2008

Journal Articles

A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Patients with Hypereosiniphilic Syndrome (HES).

Philipp le Coutre, MD, Andreas Hochhaus, MD, Dominik Heim, MD, Teresa Rafferty, MD, Aaron Weitzman, MD, Ming Zheng, MD, Gökben Baskaynak, MD, Gregor Verhoef, MD

Blood (2006) 108 (11): 4912.

https://doi.org/10.1182/blood.V108.11.4912.4912

Published: 2006

Journal Articles

A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Patients with Imatinib Resistant or Intolerant Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC) Who Have Also Failed Dasatinib Therapy.

Francis Giles, MD, Philipp le Coutre, MD, Kapil Bhalla, MD, Gianantonio Rosti, MD, G.J. Ossenkopplele, MD, Giuliana Alimena, MD, Aaron Weitzman, MD, Teresa Rafferty, Ming Zheng, MD, Hagop Kantarjian, MD

Blood (2006) 108 (11): 2170.

https://doi.org/10.1182/blood.V108.11.2170.2170

Published: 2006

Journal Articles

Natural History of Skeletal-Related Events in Patients with Multiple Myeloma: Exploratory Analysis Based on Prior History of Skeletal Complications.

Mohamad A. Hussein, Mary Kaminski, Lee Rosen, David Gordon, Ming Zheng

Blood (2004) 104 (11): 4928.

https://doi.org/10.1182/blood.V104.11.4928.4928

Published: 2004

NARROW

IDH1 Mutant AML Is Susceptible to Targeting De Novo Lipid Synthesis Independent of 2-Hydroxyglutarate and Has a Distinct Metabolic Profile from IDH2 Mutant AML

Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Patients with Hypereosiniphilic Syndrome (HES).

A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Patients with Imatinib Resistant or Intolerant Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC) Who Have Also Failed Dasatinib Therapy.

Natural History of Skeletal-Related Events in Patients with Multiple Myeloma: Exploratory Analysis Based on Prior History of Skeletal Complications.

Email alerts

ASH Publications

American Society of Hematology

IDH1 Mutant AML Is Susceptible to Targeting De Novo Lipid Synthesis Independent of 2-Hydroxyglutarate and Has a Distinct Metabolic Profile from IDH2 Mutant AML

Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Patients with Hypereosiniphilic Syndrome (HES).

A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Patients with Imatinib Resistant or Intolerant Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC) Who Have Also Failed Dasatinib Therapy.

Natural History of Skeletal-Related Events in Patients with Multiple Myeloma: Exploratory Analysis Based on Prior History of Skeletal Complications.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only